twoXAR Pharmaceuticals, a United States-based drug discovery and development company, has named Howard Rosen as its new director, it was reported on Wednesday.
Rosen has over 25 years of experience in pharmaceutical and biotechnology leadership and strategy. He has held senior leadership positions in various companies including Gilead Sciences Inc and ALZA Corporation. He serves as a board member with AcelRx Pharmaceuticals Inc, Kala Pharmaceuticals Inc, Entrega Inc, Metera Pharmaceuticals Inc and Hammerton Inc.
Andrew Radin, twoXAR CEO, said, 'We are thrilled to have Howie join our board of directors during this exciting time as our discoveries advance closer to IND filings. He has been a trusted advisor to the company since its inception and brings a wealth of experience in leading and advising pharmaceutical companies. We are grateful to have his expertise and insight as we continue to expand our research programs and partnerships.'
Avidity Biosciences prices upsized common stock public offering
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Endo to share PFI and PFA data at American Orthopaedic Foot & Ankle Society Annual Meeting
Diamyd Medical secures Eurasian patent for insulin-based antigen therapy in type 1 diabetes
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amgen and Kyowa Kirin release rocatinlimab study results in atopic dermatitis
Hemogenyx Pharmaceuticals partners with Made Scientific to advance CAR-T therapy
Lilly's Jaypirca delivers breakthrough results in front-line CLL trial